Blood
Takeda Gets FDA Approval For Blood-Clotting Disorder Treatment
Nov
By Ben Glickman
Takeda’s treatment for a rare blood clotting disorder received approval from the U.S. Food and Drug Administration.
The FDA said Thursday it approved Adzynma, a genetically engineered protein product for enzyme replacement therapy, to treat adults and children with congenital thrombotic thrombocytopenic purpura.
The disorder, caused by a genetic mutation, causes blood clots to form in small blood vessels around patients’ bodies and is estimated to affect fewer than 1,000 people in the United States.
Patients can have severe bleeding episodes, strokes or damage to organs, and the disease may be fatal if untreated.
The FDA said the efficacy and safety of Adzynma had been demonstrated in a study comparing the treatment to plasma-based therapies in patients with cTTP.
Write to Ben Glickman at [email protected]
